

Oxytetracycline Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 3.1
 30.09.2023
 6008075-00010
 Date of first issue: 05.06.2020

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Oxytetracycline Solid Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub- : Veterinary product

stance/Mixture

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD

20 Spartan Road

1619 Spartan, South Africa

Telephone : +27119239300

E-mail address of person

responsible for the SDS

EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Skin corrosion, Category 1 H314: Causes severe skin burns and eye damage.

Serious eye damage, Category 1

Skin sensitisation, Category 1

Reproductive toxicity, Category 1A

H318: Causes serious eye damage.

H317: May cause an allergic skin reaction.

H360D: May damage the unborn child.

Short-term (acute) aquatic hazard, Cate- H400: Very toxic to aquatic life.

gory 1 Long-term (chronic) aquatic hazard, Cat-

Long-term (chronic) aquatic nazard, Cat-

egory 1

H410: Very toxic to aquatic life with long lasting

effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms







Signal word : Danger



Oxytetracycline Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 3.1
 30.09.2023
 6008075-00010
 Date of first issue: 05.06.2020

Hazard statements : H314 Causes severe skin burns and eye damage.

H317 May cause an allergic skin reaction. H360D May damage the unborn child.

H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : Prevention:

P201 Obtain special instructions before use.

P260 Do not breathe dust.

P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a

POISON CENTER/ doctor. P391 Collect spillage.

Hazardous components which must be listed on the label: oxytetracycline

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
oxytetracycline	79-57-2 201-212-8	Skin Sens. 1A; H317 Repr. 1A; H360D Aquatic Acute 1; H400 Aquatic Chronic 1; H410 ——— M-Factor (Acute aquatic toxicity): 10 M-Factor (Chronic aquatic toxicity): 10	>= 70 - < 90

For explanation of abbreviations see section 16.



Oxytetracycline Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 3.1
 30.09.2023
 6008075-00010
 Date of first issue: 05.06.2020

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention immediately.

In case of skin contact : In case of contact, immediately flush skin with plenty of water

for at least 15 minutes while removing contaminated clothing

and shoes.

Get medical attention immediately. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water

for at least 15 minutes.

If easy to do, remove contact lens, if worn.

Get medical attention immediately.

If swallowed : If swallowed, DO NOT induce vomiting.

If vomiting occurs have person lean forward.

Call a physician or poison control centre immediately.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person.

4.2 Most important symptoms and effects, both acute and delayed

Risks : May cause an allergic skin reaction.

Causes serious eye damage. May damage the unborn child.

Causes severe burns.

Causes digestive tract burns.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam



Oxytetracycline Solid Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04.04.2023 30.09.2023 6008075-00010 Date of first issue: 05.06.2020 3.1

Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- : Carbon oxides

ucts

5.3 Advice for firefighters

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions Avoid release to the environment.

> Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-



Oxytetracycline Solid Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04.04.2023 30.09.2023 6008075-00010 Date of first issue: 05.06.2020 3.1

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Do not get on skin or clothing. Advice on safe handling

Do not breathe dust. Do not swallow. Do not get in eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the

environment.

If exposure to chemical is likely during typical use, provide eye Hygiene measures

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Contaminated work clothing should not be allowed out of the workplace.

Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national

regulations.

Do not store with the following product types: Advice on common storage

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases



Oxytetracycline Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 30.09.2023 6008075-00010 Date of first issue: 05.06.2020

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form	Control parameters	Basis
		of exposure)		
oxytetracycline	79-57-2	TWA	500 μg/m3 (OEB 2)	Internal
	Further information: DSEN			
		Wipe limit	100 μg/100 cm ²	Internal

8.2 Exposure controls

Engineering measures

Use feasible engineering controls to minimize exposure to compound.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Skin and body protection : Work uniform or laboratory coat.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type : Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance : powder
Colour : light yellow
Odour : No data available
Odour Threshold : No data available

pH : 1,5 - 3,0

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : Not applicable



Oxytetracycline Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 3.1
 30.09.2023
 6008075-00010
 Date of first issue: 05.06.2020

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : Not applicable

Relative vapour density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility
Partition coefficient: n-

Auto-ignition temperature

octanol/water

No data available No data available

No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

9.2 Other information

Flammability (liquids) : Not applicable

Molecular weight : No data available

Particle size : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, han-



Oxytetracycline Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 3.1
 30.09.2023
 6008075-00010
 Date of first issue: 05.06.2020

dling or other means.

Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Information on likely routes of : Inhalation

exposure Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Components:

oxytetracycline:

Acute oral toxicity : LD50 (Rat): 4.800 mg/kg

LD50 (Mouse): 2.240 mg/kg

Remarks: Evidence of phototoxicity was observed

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of :

administration)

LD50 (Rat): 4.840 mg/kg

Application Route: Intramuscular

LD50 (Mouse): 3.500 mg/kg Application Route: Subcutaneous

Skin corrosion/irritation

Causes severe burns.

Components:

oxytetracycline:

Remarks : No data available

Serious eye damage/eye irritation

Causes serious eye damage.



Oxytetracycline Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 3.1
 30.09.2023
 6008075-00010
 Date of first issue: 05.06.2020

Components:

oxytetracycline:

Remarks : No data available

Respiratory or skin sensitisation

Skin sensitisation

May cause an allergic skin reaction.

Respiratory sensitisation

Not classified based on available information.

Components:

oxytetracycline:

Test Type : Human repeat insult patch test (HRIPT)

Result : Sensitiser

Germ cell mutagenicity

Not classified based on available information.

Components:

oxytetracycline:

Genotoxicity in vitro : Test Type: Microbial mutagenesis assay (Ames test)

Result: negative

Test Type: Mouse Lymphoma

Metabolic activation: Metabolic activation

Result: positive

Test Type: sister chromatid exchange assay Test system: Chinese hamster ovary cells

Result: equivocal

Test Type: Chromosomal aberration

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse

Cell type: Bone marrow Application Route: Oral Result: equivocal

•

Test Type: in vivo assay

Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

Germ cell mutagenicity- As-

sessment

Weight of evidence does not support classification as a germ

cell mutagen.



Oxytetracycline Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 3.1
 30.09.2023
 6008075-00010
 Date of first issue: 05.06.2020

Carcinogenicity

Not classified based on available information.

Components:

oxytetracycline:

Species : Mouse
Application Route : Oral
Exposure time : 104 weeks
Result : negative

Species : Rat
Application Route : Oral
Exposure time : 103 weeks
Result : equivocal

Target Organs : Adrenal gland, Pituitary gland

Remarks : The mechanism or mode of action may not be relevant in hu-

mans.

Carcinogenicity - Assess-

ment

Weight of evidence does not support classification as a car-

cinogen

Reproductive toxicity

May damage the unborn child.

Components:

oxytetracycline:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

Fertility: NOAEL: 18 mg/kg body weight

Result: No effects on fertility, No effect on reproduction capac-

ity, No significant adverse effects were reported

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Embryo-foetal toxicity: LOAEL: 48 mg/kg body weight Result: Postimplantation loss., Skeletal malformations

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

General Toxicity Maternal: LOAEL: 1.200 mg/kg body weight Embryo-foetal toxicity: NOAEL: 1.500 mg/kg body weight

Result: No teratogenic effects

Remarks: Maternal toxicity observed.

Test Type: Embryo-foetal development

Species: Mouse Application Route: Oral

General Toxicity Maternal: LOAEL: 1.325 mg/kg body weight Embryo-foetal toxicity: NOAEL: 2.100 mg/kg body weight

Result: No teratogenic effects



Oxytetracycline Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 30.09.2023 6008075-00010 Date of first issue: 05.06.2020

Remarks: Maternal toxicity observed.

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Intramuscular

Embryo-foetal toxicity: LOAEL: 41,5 mg/kg body weight Result: Postimplantation loss., No foetal abnormalities

Test Type: Embryo-foetal development

Species: Dog

Application Route: Intramuscular

Embryo-foetal toxicity: LOAEL: 20,75 mg/kg body weight Result: Skeletal and visceral variations, Postimplantation loss.

Reproductive toxicity - As-

sessment

Positive evidence of adverse effects on development from

human epidemiological studies.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

oxytetracycline:

Species : Rat

LOAEL : 198 mg/kg
Application Route : Oral
Exposure time : 13 Weeks
Target Organs : Bone

Remarks : No significant adverse effects were reported

Species : Mouse LOAEL : 7.990 mg/kg

Application Route : Oral Exposure time : 13 Weeks Target Organs : Bone

Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 125 mg/kg
LOAEL : 250 mg/kg
Application Route : Oral

Exposure time : 12 Months

Exposure time : 12 Months
Target Organs : Testis

Remarks : Significant toxicity observed in testing

Species : Rat

NOAEL : 40 mg/kg

LOAEL : 100 mg/kg

Application Route : Intraperitoneal

Exposure time : 14 Days



Oxytetracycline Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 3.1
 30.09.2023
 6008075-00010
 Date of first issue: 05.06.2020

Target Organs : Kidney

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

oxytetracycline:

Ingestion : Symptoms: Gastrointestinal disturbance, tooth discoloration

Remarks: May cause birth defects.

SECTION 12: Ecological information

12.1 Toxicity

Components:

oxytetracycline:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): 110 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 621 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

EC50 (Daphnia magna (Water flea)): 669 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Anabaena): 0,032 mg/l

Exposure time: 72 h

NOEC (Anabaena): 0,0031 mg/l

Exposure time: 72 h

M-Factor (Acute aquatic tox- :

icity)

10

Toxicity to microorganisms : EC50 : 17,9 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 0,2 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

M-Factor (Chronic aquatic

toxicity)

10



Oxytetracycline Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 3.1
 30.09.2023
 6008075-00010
 Date of first issue: 05.06.2020

12.2 Persistence and degradability

No data available

12.3 Bioaccumulative potential

No data available

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

12.6 Other adverse effects

Product:

Endocrine disrupting poten-

tial

The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation

REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number

ADN : UN 3077
ADR : UN 3077
RID : UN 3077
IMDG : UN 3077
IATA : UN 3077

14.2 UN proper shipping name

ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,



Oxytetracycline Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 30.09.2023 6008075-00010 Date of first issue: 05.06.2020

N.O.S.

(oxytetracycline)

ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(oxytetracycline)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(oxytetracycline)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(oxytetracycline)

IATA : Environmentally hazardous substance, solid, n.o.s.

(oxytetracycline)

14.3 Transport hazard class(es)

Class Subsidiary risks

ADN : 9
ADR : 9
RID : 9
IMDG : 9

IATA : 9

14.4 Packing group

ADN

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

ADR

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

RID

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

IMDG

Packing group : III Labels : 9

EmS Code : F-A, S-F

IATA (Cargo)

Packing instruction (cargo : 956

aircraft)

Packing instruction (LQ) : Y956



Oxytetracycline Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 3.1
 30.09.2023
 6008075-00010
 Date of first issue: 05.06.2020

Packing group : III

Labels : Miscellaneous

IATA (Passenger)

Packing instruction (passen- : 956

ger aircraft)

Packing instruction (LQ) : Y956
Packing group : III

Labels : Miscellaneous

14.5 Environmental hazards

ADN

Environmentally hazardous : yes

ADR

Environmentally hazardous : yes

rid

Environmentally hazardous : yes

IMDG

Marine pollutant : yes

IATA (Passenger)

Environmentally hazardous : yes

IATA (Cargo)

Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

DSL : not determined

AICS : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version



Oxytetracycline Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 3.1
 30.09.2023
 6008075-00010
 Date of first issue: 05.06.2020

are highlighted in the body of this document by two vertical

lines.

Full text of H-Statements

H317 : May cause an allergic skin reaction.
H360D : May damage the unborn child.
H400 : Very toxic to aquatic life.

H410 : Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Aquatic Acute : Short-term (acute) aquatic hazard
Aquatic Chronic : Long-term (chronic) aquatic hazard

Repr. : Reproductive toxicity Skin Sens. : Skin sensitisation

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008: CMR - Carcinogen, Mutagen or Reproductive Toxicant: DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Classification of the mixture:

Classification procedure:



Oxytetracycline Solid Formulation

Version 3.1	Revision Date: 30.09.2023	SDS Number: 6008075-00010	Date of last issue: 04.04.2023 Date of first issue: 05.06.2020
Skin Co	orr. 1	H314	Based on product data or assessment
Eye Da	ım. 1	H318	Based on product data or assessment
Skin Se	ens. 1	H317	Calculation method
Repr. 1	A	H360D	Calculation method
Aquatio	Acute 1	H400	Calculation method
Aquatio	Chronic 1	H410	Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN